Aegerion Pharmaceuticals to Announce Third Quarter 2012 Financial Results on
Wednesday, November 7
CAMBRIDGE, Mass., Oct. 26, 2012 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals,
Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the
development and commercialization of novel therapeutics to treat rare
disorders, announced that the Company will host a conference call and live
audio webcast at 8:30 a.m. EST on Wednesday, November 7, 2012, to provide a
business update and discuss its third quarter 2012 financial and operational
To listen to the live webcast of the call, please visit the "Investors"
section of the Company's website at www.aegerion.com. Individuals may also
participate in the call via telephone by dialing (866) 516-3002 or (760)
298-5082. Interested parties unable to join the live call may access an
archived version of the webcast on Aegerion's website following the call.
About Aegerion Pharmaceuticals, Inc.
Aegerion Pharmaceuticals is an emerging biopharmaceutical company focused on
the development and commercialization of novel, life-altering therapeutics to
treat debilitating and often fatal rare diseases. The company's lead drug
candidate, lomitapide, is in late-stage development for the treatment of
Homozygous Familial Hypercholesterolemia (HoFH), a rare life-threatening
disease characterized by severely elevated cholesterol levels.
Aegerion is motivated by its commitment to patients first, as well as its core
values of integrity, innovation, responsibility to healthcare providers and
development of employees, with a constant focus on scientific and clinical
excellence. For more information, visit www.aegerion.com.
CONTACT: Aegerion Pharmaceuticals, Inc.
Michael Lawless, VP, IR
Press spacebar to pause and continue. Press esc to stop.